Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

Guizhi Zhu, Geoffrey M. Lynn, Orit Jacobson, Kai Chen, Yi Liu, Huimin Zhang, Ying Ma, Fuwu Zhang, Rui Tian, Qianqian Ni, Siyuan Cheng, Zhantong Wang, Nan Lu, Bryant C. Yung, Zhe Wang, Lixin Lang, Xiao Fu, Albert Jin, Ido D. Weiss, Harshad Vishwasrao, Gang Niu, Hari Shroff, Dennis M. Klinman, Robert A. Seder and Xiaoyuan Chen ()
Additional contact information
Guizhi Zhu: National Institutes of Health (NIH)
Geoffrey M. Lynn: NIH
Orit Jacobson: National Institutes of Health (NIH)
Kai Chen: University of Southern California
Yi Liu: National Institutes of Health (NIH)
Huimin Zhang: National Institutes of Health (NIH)
Ying Ma: National Institutes of Health (NIH)
Fuwu Zhang: National Institutes of Health (NIH)
Rui Tian: National Institutes of Health (NIH)
Qianqian Ni: National Institutes of Health (NIH)
Siyuan Cheng: National Institutes of Health (NIH)
Zhantong Wang: National Institutes of Health (NIH)
Nan Lu: National Institutes of Health (NIH)
Bryant C. Yung: National Institutes of Health (NIH)
Zhe Wang: National Institutes of Health (NIH)
Lixin Lang: National Institutes of Health (NIH)
Xiao Fu: NIH
Albert Jin: NIH
Ido D. Weiss: NIH
Harshad Vishwasrao: National Institutes of Health
Gang Niu: National Institutes of Health (NIH)
Hari Shroff: National Institutes of Health
Dennis M. Klinman: National Cancer Institute
Robert A. Seder: NIH
Xiaoyuan Chen: National Institutes of Health (NIH)

Nature Communications, 2017, vol. 8, issue 1, 1-15

Abstract: Abstract Subunit vaccines have been investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but have rarely been clinically translated. By conjugating molecular vaccines with Evans blue (EB) into albumin-binding vaccines (AlbiVax), here we develop clinically promising albumin/AlbiVax nanocomplexes that self-assemble in vivo from AlbiVax and endogenous albumin for efficient vaccine delivery and potent cancer immunotherapy. PET pharmacoimaging, super-resolution microscopies, and flow cytometry reveal almost 100-fold more efficient co-delivery of CpG and antigens (Ags) to lymph nodes (LNs) by albumin/AlbiVax than benchmark incomplete Freund’s adjuvant (IFA). Albumin/AlbiVax elicits ~10 times more frequent peripheral antigen-specific CD8+ cytotoxic T lymphocytes with immune memory than IFA-emulsifying vaccines. Albumin/AlbiVax specifically inhibits progression of established primary or metastatic EG7.OVA, B16F10, and MC38 tumors; combination with anti-PD-1 and/or Abraxane further potentiates immunotherapy and eradicates most MC38 tumors. Albumin/AlbiVax nanocomplexes are thus a robust platform for combination cancer immunotherapy.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-017-02191-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-02191-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-02191-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().